Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 49

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Scientific considerations for the regulatory evaluation of cell therapy products

Petricciani, John, Hayakawa, Takao, Stacey, Glyn, Trouvin, Jean-Hugues, Knezevic, Ivana · 2017 · Biologicals

Abstract

Cell therapy involves the administration of a viable somatic cell preparation to a patient for the treatment of a disease or traumatic damage. Because cell therapies are complex and very different from traditional biological products, they present significant challenges for regulatory authorities, manufacturers, developers, health care providers, and patients involved in their application. Like other emerging areas of biomedical research and development, there are many issues where regulatory views and decisions among countries and regions may differ due to minimal scientific evidence to support safety and efficacy, and lack of experience with these novel treatments. A brief overview of the current regulatory landscape for cell-based therapies is presented, and the need for a global effort to develop a set of common principles that may serve to facilitate the regulatory evaluation and market availability of these products is identified. In addition, a number of elements that could form a core consensus package of requirements for evaluating human cell therapy products is presented in the supplemental material which should be read in conjunction with the manuscript.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.biologicals.2017.08.011

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Figures

Image 1
CC-BY-NC-ND · From the PDF
Fig. 1 Examples of the numerous elements that may make up a cell therapy manufacturing process.
Fig. 1 Examples of the numerous elements that may make up a cell therapy manufacturing process.CC-BY-NC-ND · From the PDF
Fig. 2 Changes in cell sources 1998 e 2015*.
Fig. 2 Changes in cell sources 1998 e 2015*.CC-BY-NC-ND · From the PDF
2015*.
2015*.CC-BY-NC-ND · From the PDF
Fig. 4 CTPs with market approval per country*.
Fig. 4 CTPs with market approval per country*.CC-BY-NC-ND · From the PDF
Fig. 5 CTP Guidelines per country.
Fig. 5 CTP Guidelines per country.CC-BY-NC-ND · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Research works printed but not linked: 3

  1. 2007, Regulation (EC) No 1394/2007 of the European parliament and of the council on advanced therapy medicinal products and amending directive 2001/83/EC and regulation (EC) No 726/2004, OJ, L324, 121e37
  2. 2001, Directive (EC) 2001/83 of the European Parliament and of the Council on the Community code relating to medicinal products for human use, OJ, L311, 67
  3. 2004, Directive 2004/23/EC of the European Parliament and of the Council of 31 March 2004 on setting standards of quality and safety for the donation, procurement, testing, processing, preservation, storage and distribution of human tissues and cells, OJ, L102, 48e58

Metadata

Authors
Petricciani, J., Hayakawa, T., Stacey, G., Trouvin, J.-H., & Knezevic, I.
Venue
Biologicals
Publisher
Elsevier BV
Published
2017-11
Volume
50
Pages
20-26
ISSN
1045-1056
Cited by
49
References
20
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Scientific considerations for the regulatory evaluation of cell therapy products. https://app.cochat.ai/papers/10.1016/j.biologicals.2017.08.011
The paper
Petricciani, J., Hayakawa, T., Stacey, G., Trouvin, J.-H., & Knezevic, I. (2017). Scientific considerations for the regulatory evaluation of cell therapy products. Biologicals. https://doi.org/10.1016/j.biologicals.2017.08.011

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.